Inhaled Fluticasone for Outpatient Treatment of Covid-19: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial

Accelerating Covid-19 Therapeutic Interventions and Vaccines (ACTIV)-6 Study Group, Susanna Naggie
doi: https://doi.org/10.1101/2022.07.12.22277548

Article Information

doi 
https://doi.org/10.1101/2022.07.12.22277548
History 
  • August 11, 2022.

Article Versions

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Author Information

  1. Accelerating Covid-19 Therapeutic Interventions and Vaccines (ACTIV)-6 Study Group* and
  2. Susanna Naggie1,#
  1. 1Duke University School of Medicine
  1. ↵#Corresponding author; email: susanna.naggie{at}duke.edu
Back to top
Posted August 11, 2022.
Download PDF

Supplementary Material

Data/Code
Email
Inhaled Fluticasone for Outpatient Treatment of Covid-19: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial
Accelerating Covid-19 Therapeutic Interventions and Vaccines (ACTIV)-6 Study Group, Susanna Naggie
medRxiv 2022.07.12.22277548; doi: https://doi.org/10.1101/2022.07.12.22277548
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area